Blood test for PMDD on the horizon? johns hopkins launches biomarker study

NCT ID NCT06771583

Recruiting now Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study from Johns Hopkins aims to find epigenetic markers in blood that could help identify premenstrual dysphoric disorder (PMDD). Researchers will collect blood samples and track mood changes across the menstrual cycle in 500 women — some with PMDD and some without. The goal is to see if certain DNA markers differ between the groups, which could lead to better diagnosis and understanding of the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could point toward a biological test to diagnose PMDD and predict who might respond to certain treatments.
What could go wrong: This is an early observational study, not a treatment trial. The biomarkers may not reliably distinguish PMDD from controls, and results may not lead to a clinical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENSTRUAL CYCLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

premenstrual dysphoric disorder premenstrual tension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENSTRUAL CYCLE PMDD PREMENSTRUAL DYSPHORIC DISORDER ( PMDD) PREMENSTRUAL SYNDROME PREMENSTRUAL SYNDROME-PMS

Contacts and locations

Locations

Johns Hopkins Reproductive Mental Health Center
RECRUITING

Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.